文献速递心血管US

中度主动脉瓣狭窄预后表型的定义与验证

Definition and Validation of Prognostic Phenotypes in Moderate Aortic Stenosis.
PubMed 文献 · JACC Cardiovasc Imaging · 2024-08-14

研究对2469例中度主动脉瓣狭窄患者进行无监督聚类,识别出心血管合并症型、低流速型、钙化瓣膜型和低危型四种表型,并在1358例独立队列中验证。心血管合并症型风险最高(验证HR 2.00),钙化瓣膜型患者接受主动脉瓣置换后结局显著改善(验证HR 0.21),其余3种表型未见显著获益。

要点

  • 中度主动脉瓣狭窄可分为心血管合并症型、低流速型、钙化瓣膜型和低危型四种预后表型。
  • 心血管合并症型预后最差,验证队列HR为2.00(95%CI 1.54-2.59)。
  • 钙化瓣膜型患者主动脉瓣置换后结局改善(验证HR 0.21,95%CI 0.08-0.57)。

核心结论

  • 中度主动脉瓣狭窄存在多种预后表型,多重合并症是不良结局的关键驱动因素;非钙化性中度主动脉瓣狭窄患者的结局未因主动脉瓣置换而改变。

研究设计与样本

  • 研究采用无监督聚类算法,训练集为2469例中度主动脉瓣狭窄患者,外部验证集为1358例独立患者,评估5年内心源性死亡、心力衰竭住院或主动脉瓣干预的复合终点。

诊断标准与关键数值

  • 基于人口学、合并症和超声心动图参数的无监督聚类识别出四种表型:心血管合并症型、低流速型、钙化瓣膜型和低危型。
  • 验证队列中心血管合并症型复合终点风险最高,HR为2.00(95%CI 1.54-2.59),P<0.001。
  • 钙化瓣膜型患者主动脉瓣置换后复合终点发生率显著降低,验证HR为0.21(95%CI 0.08-0.57),P=0.002;其余3种表型未见显著影响。

临床应用与阅片要点

  • 作者认为,根据风险对中度主动脉瓣狭窄患者进行表型分型可能有助于决策制定。
  • 作者指出,仔细关注中度主动脉瓣狭窄的亚组对于定义可治疗风险可能很重要。

局限性

  • 这些分析受到主动脉瓣置换率低的限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Adverse outcomes from moderate aortic stenosis (AS) may be caused by progression to severe AS or by the effects of comorbidities. In the absence of randomized trial evidence favoring aortic valve replacement (AVR) in patients with moderate AS, phenotyping patients according to risk may assist decision making.

OBJECTIVES: This study sought to identify and validate clusters of moderate AS that may be used to guide patient management.

METHODS: Unsupervised clustering algorithms were applied to demographics, comorbidities, and echocardiographic parameters in a training data set in patients with moderate AS (n = 2,469). External validation was obtained by assigning the defined clusters to an independent group with moderate AS (n = 1,358). The primary outcome, a composite of cardiac death, heart failure hospitalization, or aortic valve (AV) intervention after 5 years, was assessed between clusters in both data sets.

RESULTS: Four distinct clusters-cardiovascular (CV)-comorbid, low-flow, calcified AV, and low-risk-with significant outcomes (log-rank P < 0.0001 in both data sets) were identified and replicated. The highest risk was in the CV-comorbid cluster (validation HR: 2.00 [95% CI: 1.54-2.59]; P < 0.001). The effect of AVR on cardiac death differed among the clusters. There was a significantly lower rate of outcomes after AVR in the calcified AV cluster (validation HR: 0.21 [95% CI: 0.08-0.57]; P = 0.002), but no significant effect on outcomes in the other 3 clusters. These analyses were limited by the low rate of AVR.

CONCLUSIONS: Moderate AS has several phenotypes, and multiple comorbidities are the key drivers of adverse outcomes in patients with moderate AS. Outcomes of patients with noncalcified moderate AS were not altered by AVR in these groups. Careful attention to subgroups of moderate AS may be important to define treatable risk.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Sen J, Wahi S, Vollbon W, et al. Definition and Validation of Prognostic Phenotypes in Moderate Aortic Stenosis. JACC Cardiovasc Imaging. 2024. PMID: 39152961. doi:10.1016/j.jcmg.2024.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。